Company / Cost of Revenue
ELITE PHARMACEUTICALS INC /NV/ Cost of Revenue History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$44.0M
FY2024
5-year range
$17.5M / $44.0M
FY2020-FY2024
Trend
+45.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has increased for 7 consecutive years, from $4M in FY2017 to $44M in FY2024.
Based on SEC 10-K filings.
$44M in FY2024 with a 5-year CAGR of +34.4%.
Increased from $18M to $44M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +36.0%
- 5-Year CAGR
- +34.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- ELITE PHARMACEUTICALS INC /NV/'s cost of revenue has grown for 7 consecutive years.
- 5-year CAGR of +34.4%, indicating consistent growth.
- In FY2024, cost of revenue increased 45.2% year-over-year.
- Lowest cost of revenue in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $44.0M | +45.2% |
| FY2023 | $30.3M | +72.4% |
| FY2022 | $17.6M | +0.5% |
| FY2021 | $17.5M | +29.3% |
| FY2020 | $13.5M | +34.9% |
| FY2019 | $10.0M | +113.1% |
| FY2018 | $4.7M | +33.9% |
| FY2017 | $3.5M | -40.5% |
| FY2016 | $5.9M | +31.5% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026